JP2017538659A - Smyd阻害剤 - Google Patents
Smyd阻害剤 Download PDFInfo
- Publication number
- JP2017538659A JP2017538659A JP2017512982A JP2017512982A JP2017538659A JP 2017538659 A JP2017538659 A JP 2017538659A JP 2017512982 A JP2017512982 A JP 2017512982A JP 2017512982 A JP2017512982 A JP 2017512982A JP 2017538659 A JP2017538659 A JP 2017538659A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- tumor
- alkyl
- cell
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(CN(C)**)NC(*)=O Chemical compound CC(CN(C)**)NC(*)=O 0.000 description 21
- MNOYPAPEMHJDTI-UHFFFAOYSA-N CC(C(C1Cl)C=CC=C1OCCO)N(C1)CC1NC(c1c[n](C2C3C2C3)nn1)=O Chemical compound CC(C(C1Cl)C=CC=C1OCCO)N(C1)CC1NC(c1c[n](C2C3C2C3)nn1)=O MNOYPAPEMHJDTI-UHFFFAOYSA-N 0.000 description 1
- HUIGBYWECUZYHU-VUWPPUDQSA-N CC(C(CC1)CCN1C([C@H](C)N)=O)NC(c(cc1)cc(O2)c1NC2=O)=O Chemical compound CC(C(CC1)CCN1C([C@H](C)N)=O)NC(c(cc1)cc(O2)c1NC2=O)=O HUIGBYWECUZYHU-VUWPPUDQSA-N 0.000 description 1
- JRSPHVFVKVVJDP-DTIOYNMSSA-N CC(C(CC1)CCN1C([C@H](C)NC(OC(C)(C)C)=O)=O)N Chemical compound CC(C(CC1)CCN1C([C@H](C)NC(OC(C)(C)C)=O)=O)N JRSPHVFVKVVJDP-DTIOYNMSSA-N 0.000 description 1
- NPTGRCJRHXYNGM-UHFFFAOYSA-N CC(C(Nc(cc(CC(OC)=O)cc1)c1O)=O)Br Chemical compound CC(C(Nc(cc(CC(OC)=O)cc1)c1O)=O)Br NPTGRCJRHXYNGM-UHFFFAOYSA-N 0.000 description 1
- KSMVBYPXNKCPAJ-UHFFFAOYSA-N CC(CC1)CCC1N Chemical compound CC(CC1)CCC1N KSMVBYPXNKCPAJ-UHFFFAOYSA-N 0.000 description 1
- DEOUZFWSQWEPGE-ZETCQYMHSA-N CCCCC[C@H](C)C(N)=O Chemical compound CCCCC[C@H](C)C(N)=O DEOUZFWSQWEPGE-ZETCQYMHSA-N 0.000 description 1
- FDRFYJLDMNDLKE-UHFFFAOYSA-N CCc1c[n](Cc2ncc[o]2)nc1 Chemical compound CCc1c[n](Cc2ncc[o]2)nc1 FDRFYJLDMNDLKE-UHFFFAOYSA-N 0.000 description 1
- NXXRECPEBNIVOH-PXYINDEMSA-N CCc1cc(C(NC(CC2)C[C@H](C)N2C(OC(C)(C)C)=O)=O)n[s]1 Chemical compound CCc1cc(C(NC(CC2)C[C@H](C)N2C(OC(C)(C)C)=O)=O)n[s]1 NXXRECPEBNIVOH-PXYINDEMSA-N 0.000 description 1
- NOWLUZBZMJWZRW-UHFFFAOYSA-N CCc1cc(C(O)O)nnc1 Chemical compound CCc1cc(C(O)O)nnc1 NOWLUZBZMJWZRW-UHFFFAOYSA-N 0.000 description 1
- FQLPTTQGGQPXDP-HHSWWEEVSA-N CCc1cnnc(C(NC(CC[C@H]2CC3C4)CC[C@]34N2S(N(CC2)CCC2N)(=O)=O)=O)c1 Chemical compound CCc1cnnc(C(NC(CC[C@H]2CC3C4)CC[C@]34N2S(N(CC2)CCC2N)(=O)=O)=O)c1 FQLPTTQGGQPXDP-HHSWWEEVSA-N 0.000 description 1
- PQERTOAPKBEDTO-NXGOIJHOSA-N C[C@@H](C[C@H](CC1)NC(c(cc2)cc(C3)c2NC3=O)O)N1S(c(cc1)ccc1NC(C)=O)(=O)=O Chemical compound C[C@@H](C[C@H](CC1)NC(c(cc2)cc(C3)c2NC3=O)O)N1S(c(cc1)ccc1NC(C)=O)(=O)=O PQERTOAPKBEDTO-NXGOIJHOSA-N 0.000 description 1
- KSMVBYPXNKCPAJ-LJGSYFOKSA-N C[C@H](CC1)CC[C@@H]1N Chemical compound C[C@H](CC1)CC[C@@H]1N KSMVBYPXNKCPAJ-LJGSYFOKSA-N 0.000 description 1
- PKVFZJADFGHKEM-GJMOJQLCSA-N C[C@H](CC1)[C@@H](C)C[C@@H]1N Chemical compound C[C@H](CC1)[C@@H](C)C[C@@H]1N PKVFZJADFGHKEM-GJMOJQLCSA-N 0.000 description 1
- CTHOPHSWTMBPAH-ZCFIWIBFSA-N C[C@H](CCCCN)C(N)=O Chemical compound C[C@H](CCCCN)C(N)=O CTHOPHSWTMBPAH-ZCFIWIBFSA-N 0.000 description 1
- MBUZPLVFYBXHCH-UHFFFAOYSA-N Cc(cc(CC(N1)=O)c1c1)c1Cl Chemical compound Cc(cc(CC(N1)=O)c1c1)c1Cl MBUZPLVFYBXHCH-UHFFFAOYSA-N 0.000 description 1
- MXKUQDJSQDHVPI-UHFFFAOYSA-N Cc1c[n](C2CC2)nn1 Chemical compound Cc1c[n](C2CC2)nn1 MXKUQDJSQDHVPI-UHFFFAOYSA-N 0.000 description 1
- LDGSZLZAJODXBX-UHFFFAOYSA-N Cc1c[n](Cc(cc2)ccc2Cl)nc1 Chemical compound Cc1c[n](Cc(cc2)ccc2Cl)nc1 LDGSZLZAJODXBX-UHFFFAOYSA-N 0.000 description 1
- OXFRFQTZKFRTMG-UHFFFAOYSA-N Cc1cc(C2CC2)ccn1 Chemical compound Cc1cc(C2CC2)ccn1 OXFRFQTZKFRTMG-UHFFFAOYSA-N 0.000 description 1
- YZQGRYUHJJECPA-UHFFFAOYSA-N Cc1cc(C2CC2)cnn1 Chemical compound Cc1cc(C2CC2)cnn1 YZQGRYUHJJECPA-UHFFFAOYSA-N 0.000 description 1
- QNRMRLIREBQQDD-UHFFFAOYSA-N NC(CC1)CCC1NC(c1c[n](C2CC2)nn1)=O Chemical compound NC(CC1)CCC1NC(c1c[n](C2CC2)nn1)=O QNRMRLIREBQQDD-UHFFFAOYSA-N 0.000 description 1
- HRXXRFPYGJSACA-IRXJBOGLSA-N NC(CC1)CCN1S(N([C@H](CC1)C2)[C@@H]1C[C@H]2NC(c(c(Cl)c1)cc2c1NC1OC1C2)O)(=O)=O Chemical compound NC(CC1)CCN1S(N([C@H](CC1)C2)[C@@H]1C[C@H]2NC(c(c(Cl)c1)cc2c1NC1OC1C2)O)(=O)=O HRXXRFPYGJSACA-IRXJBOGLSA-N 0.000 description 1
- BIDDWSZEXHPZDK-UHFFFAOYSA-N O=C(C1)Nc2c1cc(CNCC1CCNCC1)cc2 Chemical compound O=C(C1)Nc2c1cc(CNCC1CCNCC1)cc2 BIDDWSZEXHPZDK-UHFFFAOYSA-N 0.000 description 1
- GFZPRBUSSIXTOC-UHFFFAOYSA-N OC(c1nncc(C2CC2)c1)=O Chemical compound OC(c1nncc(C2CC2)c1)=O GFZPRBUSSIXTOC-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/18—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
- C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Indole Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462048773P | 2014-09-10 | 2014-09-10 | |
| US62/048,773 | 2014-09-10 | ||
| US201562146799P | 2015-04-13 | 2015-04-13 | |
| US62/146,799 | 2015-04-13 | ||
| PCT/US2015/049221 WO2016040505A1 (en) | 2014-09-10 | 2015-09-09 | Smyd inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020013314A Division JP2020090520A (ja) | 2014-09-10 | 2020-01-30 | Smyd阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017538659A true JP2017538659A (ja) | 2017-12-28 |
| JP2017538659A5 JP2017538659A5 (enExample) | 2018-10-18 |
Family
ID=55459528
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017512982A Pending JP2017538659A (ja) | 2014-09-10 | 2015-09-09 | Smyd阻害剤 |
| JP2020013314A Pending JP2020090520A (ja) | 2014-09-10 | 2020-01-30 | Smyd阻害剤 |
| JP2022118248A Pending JP2022163087A (ja) | 2014-09-10 | 2022-07-25 | Smyd阻害剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020013314A Pending JP2020090520A (ja) | 2014-09-10 | 2020-01-30 | Smyd阻害剤 |
| JP2022118248A Pending JP2022163087A (ja) | 2014-09-10 | 2022-07-25 | Smyd阻害剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10266526B2 (enExample) |
| EP (1) | EP3193600A4 (enExample) |
| JP (3) | JP2017538659A (enExample) |
| KR (2) | KR102496364B1 (enExample) |
| CN (2) | CN107072205B (enExample) |
| AU (1) | AU2015315174B2 (enExample) |
| BR (1) | BR112017004612A2 (enExample) |
| CA (1) | CA2960275A1 (enExample) |
| EA (1) | EA201790317A1 (enExample) |
| IL (2) | IL250891A0 (enExample) |
| MX (2) | MX2017002985A (enExample) |
| SG (2) | SG10201901192TA (enExample) |
| WO (1) | WO2016040505A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021536428A (ja) * | 2018-08-14 | 2021-12-27 | エピザイム,インコーポレイティド | 置換インドール及びその使用方法 |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| RU2569678C2 (ru) | 2010-04-22 | 2015-11-27 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения циклоалкилкарбоксамидо-индольных соединений |
| PT3131582T (pt) | 2014-04-15 | 2018-10-08 | Vertex Pharma | Composições farmacêuticas para o tratamento de doenças mediadas pelo regulador de condutância transmembranar da fibrose quística |
| MX2017002986A (es) | 2014-09-10 | 2017-10-24 | Epizyme Inc | Compuestos de piperidina sustituidos. |
| JP2017526706A (ja) | 2014-09-10 | 2017-09-14 | エピザイム,インコーポレイティド | イソオキサゾールカルボキサミド化合物 |
| JP2017528460A (ja) | 2014-09-10 | 2017-09-28 | エピザイム インコーポレイテッド | 不可逆的smyd阻害剤としてのイソオキサゾールカルボキサミド |
| AU2015315171A1 (en) | 2014-09-10 | 2017-03-16 | Epizyme, Inc. | Substituted cyclohexylamine compounds |
| WO2018030550A1 (en) | 2016-08-09 | 2018-02-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds with an ror(gamma)t modulating activity |
| WO2018151678A1 (en) * | 2017-02-15 | 2018-08-23 | Agency For Science, Technology And Research | Compounds for treatment of cancer and epigenetics |
| AU2018231120B2 (en) * | 2017-03-10 | 2022-06-23 | Rutgers, The State University Of New Jersey | Indole derivatives as efflux pump inhibitors |
| US20200138827A1 (en) * | 2017-06-22 | 2020-05-07 | Curadev Pharma Limited | Small molecule modulators of human sting |
| AU2018288018C1 (en) | 2017-06-22 | 2022-10-20 | Curadev Pharma Limited | Small molecule modulators of human STING |
| CA3072746A1 (en) | 2017-08-14 | 2019-02-21 | Epizyme, Inc. | Methods of treating cancer by inhibiting setd2 |
| WO2020092394A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
| DK3873884T3 (da) | 2018-10-30 | 2025-02-17 | Gilead Sciences Inc | 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme |
| EP3873897B1 (en) | 2018-10-30 | 2024-08-14 | Gilead Sciences, Inc. | N-benzoyl-phenylalanine derivatives as alpha4beta7 integrin inhibitors for treating inflammatory diseases |
| PL3873605T3 (pl) | 2018-10-30 | 2025-03-03 | Gilead Sciences, Inc. | Związki hamujące integrynę alfa4beta7 |
| EP4010341A1 (en) * | 2019-08-08 | 2022-06-15 | Université de Strasbourg | Trkb positive allosteric modulators |
| US11578069B2 (en) | 2019-08-14 | 2023-02-14 | Gilead Sciences, Inc. | Compounds for inhibition of α4 β7 integrin |
| PH12022551379A1 (en) | 2019-12-06 | 2023-05-03 | Vertex Pharma | Substituted tetrahydrofurans as modulators of sodium channels |
| WO2021134004A1 (en) * | 2019-12-27 | 2021-07-01 | Schrodinger, Inc. | Cyclic compounds and methods of using same |
| US20230133671A1 (en) * | 2020-02-19 | 2023-05-04 | Epizyme, Inc. | Setd2 inhibitors and related methods and uses, including combination therapies |
| WO2021257544A1 (en) | 2020-06-16 | 2021-12-23 | Icahn School Of Medicine At Mount Sinai | Sox11 inhibitors for treating mantle cell lymphoma |
| EP4263535A1 (en) | 2020-12-17 | 2023-10-25 | Astrazeneca AB | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides |
| DK4347031T3 (da) | 2021-06-04 | 2025-12-01 | Vertex Pharma | N-(hydroxyalkyl-(hetero)aryl)-tetrahydrofuran-carboxamider som modulatorer af natriumkanaler |
| CN114246851B (zh) * | 2021-11-09 | 2024-01-26 | 澳门科技大学 | 一种组蛋白甲基转移酶smyd3小分子抑制剂的合成方法及用途 |
| CN114702552B (zh) * | 2022-03-11 | 2024-05-31 | 苏州思萃免疫技术研究所有限公司 | mTORC2抑制剂 |
| WO2023192665A2 (en) * | 2022-04-01 | 2023-10-05 | Praxis Precision Medicines, Inc. | T-type calcium channel modulators and methods of use thereof |
| GB2620976B (en) * | 2022-07-28 | 2024-07-24 | Jones Paul | Amido-amine hardener |
| CN120981228A (zh) * | 2022-11-17 | 2025-11-18 | 腾维治疗公司 | 化合物、组合物和方法 |
| CN120882411A (zh) * | 2022-11-17 | 2025-10-31 | 腾维治疗公司 | 化合物、组合物和方法 |
| WO2024158863A1 (en) * | 2023-01-25 | 2024-08-02 | The Rockefeller University | Sulfonamide-1h-pyrrole-2-carboxamide inhibitors of sars-cov-2 nsp14 methyltransferase and derivatives thereof |
| CN116327748B (zh) * | 2023-04-21 | 2024-09-17 | 武汉科技大学 | 联合用药物在制备抗肿瘤药物中的用途 |
| WO2025165834A1 (en) * | 2024-01-31 | 2025-08-07 | Ensem Therapeutics, Inc. | Urea derivatives of tricyclic compounds, and compositions and methods thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009518423A (ja) * | 2005-12-08 | 2009-05-07 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | 統合失調症の副作用および陰性症状を治療するためのcb1アンタゴニストの使用 |
| JP2009542809A (ja) * | 2006-07-12 | 2009-12-03 | メルク エンド カムパニー インコーポレーテッド | グレリン受容体アンタゴニストとしての置換ピラゾール |
| WO2012168361A1 (en) * | 2011-06-10 | 2012-12-13 | Syngenta Participations Ag | Novel insecticides |
| JP2014517019A (ja) * | 2011-06-17 | 2014-07-17 | バジリア ファルマスーチカ アーゲー | 三環式抗生物質 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1441195A (en) * | 1993-12-30 | 1995-07-17 | Smithkline Beecham Corporation | Phenylmethyl hexanamides, and the use thereof |
| WO1998022432A1 (en) * | 1996-11-18 | 1998-05-28 | Yamanouchi Pharmaceutical Co., Ltd. | Novel acylamino-substituted acylanilide derivatives or pharmaceutical composition comprising the same |
| CZ20021009A3 (cs) * | 1999-09-21 | 2002-06-12 | Astrazeneca Ab | Deriváty chinazolinu, způsob jejich přípravy a jejich pouľití jako léčiv |
| US6867299B2 (en) * | 2000-02-24 | 2005-03-15 | Hoffmann-La Roche Inc. | Oxamide IMPDH inhibitors |
| TWI290136B (en) * | 2000-04-05 | 2007-11-21 | Daiichi Seiyaku Co | Ethylenediamine derivatives |
| CA2415961A1 (en) | 2000-07-19 | 2002-01-24 | Hirohiko Nishiyama | Production method of 1-substituted-1,2,3-triazole derivatives |
| AUPR034000A0 (en) * | 2000-09-25 | 2000-10-19 | Fujisawa Pharmaceutical Co., Ltd. | Aminoalcohol derivatives |
| AU2002338334B8 (en) * | 2001-04-03 | 2008-09-18 | Merck & Co., Inc. | N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B antagonists |
| EP1314733A1 (en) * | 2001-11-22 | 2003-05-28 | Aventis Pharma Deutschland GmbH | Indole-2-carboxamides as factor Xa inhibitors |
| GB0205176D0 (en) * | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| JP2004175739A (ja) * | 2002-11-28 | 2004-06-24 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| JP2004315395A (ja) * | 2003-04-14 | 2004-11-11 | Yamanouchi Pharmaceut Co Ltd | 新規な安息香酸誘導体又はその塩 |
| GB0317516D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as PDE4 inhibitors |
| CA2538759C (en) * | 2003-09-12 | 2015-11-03 | Elixir Pharmaceuticals, Inc. | Substituted heterocyclic compounds as sirtuin inhitibitors |
| JP2007518823A (ja) * | 2004-01-23 | 2007-07-12 | アムゲン インコーポレイテッド | キノリン、キナゾリン、ピリジン、及びピリミジン化合物と炎症、血管新生、及び癌に対する治療におけるそれら化合物の用途 |
| EP1718611A4 (en) * | 2004-02-13 | 2009-09-23 | Harvard College | 3-3-DI-SUBSTITUTED OXINDOLES AS INHIBITORS OF INITIATION OF TRANSLATION |
| JP2006089485A (ja) * | 2004-08-24 | 2006-04-06 | Santen Pharmaceut Co Ltd | ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体 |
| CA2588607A1 (en) * | 2004-11-23 | 2006-06-01 | Ptc Therapeutics, Inc. | Carbazole, carboline and indole derivatives useful in the inhibition of vegf production |
| US20090253671A1 (en) * | 2005-03-04 | 2009-10-08 | Astrazeneca Ab | Tricyclic derivatives of azetidine and pyrrole with antibacterial activity |
| AU2006232620A1 (en) * | 2005-04-06 | 2006-10-12 | Astrazeneca Ab | Substituted heterocycles and their use as CHK1, PDK1 and PAK inhibitors |
| WO2007002220A2 (en) * | 2005-06-21 | 2007-01-04 | Bristol-Myers Squibb Company | Aminoacetamide acyl guanidines as beta-secretase inhibitors |
| TW200741009A (en) * | 2005-07-01 | 2007-11-01 | Oncotherapy Science Inc | Methods of modulating SMYD3 for treatment of cancer |
| GB0525083D0 (en) * | 2005-12-09 | 2006-01-18 | Astrazeneca Ab | Pyrimidine derivatives |
| US7838542B2 (en) * | 2006-06-29 | 2010-11-23 | Kinex Pharmaceuticals, Llc | Bicyclic compositions and methods for modulating a kinase cascade |
| WO2008016666A2 (en) * | 2006-08-02 | 2008-02-07 | Cytokinetics, Incorporated | Certain chemical entities, compositions, and methods |
| JP2010513263A (ja) * | 2006-12-15 | 2010-04-30 | ファイザー・プロダクツ・インク | ベンズイミダゾール誘導体 |
| CA2672373C (en) * | 2006-12-19 | 2011-08-30 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
| PE20091576A1 (es) * | 2008-02-19 | 2009-11-05 | Sanofi Aventis | DERIVADOS DE 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA COMO INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3 |
| WO2009143039A2 (en) * | 2008-05-19 | 2009-11-26 | Schering Corporation | Heterocyclic compounds as factor ixa inhibitors |
| TW201010997A (en) | 2008-06-18 | 2010-03-16 | Pfizer Ltd | Nicotinamide derivatives |
| ES2620027T3 (es) * | 2008-09-03 | 2017-06-27 | Biomarin Pharmaceutical Inc. | Composiciones que incluyen derivados del ácido 6-aminohexanoico como inhibidores de HDAC |
| WO2012050393A2 (ko) * | 2010-10-14 | 2012-04-19 | 제이더블유중외제약 주식회사 | 리버스-턴 유사체의 신규한 화합물 및 그 제조방법과 용도 |
| CA2820035A1 (en) * | 2010-12-08 | 2012-06-14 | Lycera Corporation | Cycloalkyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof |
| WO2012135697A2 (en) * | 2011-03-30 | 2012-10-04 | H. Lee Moffitt Cancer Center & Research Institute Inc. | Novel rho kinase inhibitors and methods of use |
| US9145412B2 (en) * | 2012-11-02 | 2015-09-29 | Acetylon Pharmaceuticals, Inc. | Selective HDAC1 and HDAC2 inhibitors |
| CN103877078B (zh) * | 2012-12-20 | 2017-03-15 | 上海交通大学医学院 | Senp2小分子抑制剂及其应用 |
| JP2017526706A (ja) | 2014-09-10 | 2017-09-14 | エピザイム,インコーポレイティド | イソオキサゾールカルボキサミド化合物 |
| US20170247326A1 (en) | 2014-09-10 | 2017-08-31 | Epizyme, Inc. | Substituted Pyrrolidine Carboxamide Compounds |
| AU2015315171A1 (en) | 2014-09-10 | 2017-03-16 | Epizyme, Inc. | Substituted cyclohexylamine compounds |
| MX2017002986A (es) | 2014-09-10 | 2017-10-24 | Epizyme Inc | Compuestos de piperidina sustituidos. |
| JP2017528460A (ja) | 2014-09-10 | 2017-09-28 | エピザイム インコーポレイテッド | 不可逆的smyd阻害剤としてのイソオキサゾールカルボキサミド |
| US20170253601A1 (en) | 2014-09-10 | 2017-09-07 | Epizyme, Inc. | Substituted Pyrrolidine Compounds |
-
2015
- 2015-09-09 KR KR1020177009602A patent/KR102496364B1/ko active Active
- 2015-09-09 MX MX2017002985A patent/MX2017002985A/es unknown
- 2015-09-09 CA CA2960275A patent/CA2960275A1/en active Pending
- 2015-09-09 BR BR112017004612-1A patent/BR112017004612A2/pt not_active Application Discontinuation
- 2015-09-09 EA EA201790317A patent/EA201790317A1/ru unknown
- 2015-09-09 WO PCT/US2015/049221 patent/WO2016040505A1/en not_active Ceased
- 2015-09-09 CN CN201580060859.4A patent/CN107072205B/zh not_active Expired - Fee Related
- 2015-09-09 SG SG10201901192TA patent/SG10201901192TA/en unknown
- 2015-09-09 US US15/510,586 patent/US10266526B2/en active Active
- 2015-09-09 CN CN202210734932.3A patent/CN115028619A/zh active Pending
- 2015-09-09 JP JP2017512982A patent/JP2017538659A/ja active Pending
- 2015-09-09 AU AU2015315174A patent/AU2015315174B2/en not_active Ceased
- 2015-09-09 EP EP15840789.0A patent/EP3193600A4/en not_active Withdrawn
- 2015-09-09 KR KR1020237003762A patent/KR20230026515A/ko not_active Ceased
- 2015-09-09 SG SG11201701598PA patent/SG11201701598PA/en unknown
-
2017
- 2017-03-02 IL IL250891A patent/IL250891A0/en unknown
- 2017-03-07 MX MX2023006257A patent/MX2023006257A/es unknown
-
2019
- 2019-02-06 US US16/269,338 patent/US20190322660A1/en not_active Abandoned
-
2020
- 2020-01-30 JP JP2020013314A patent/JP2020090520A/ja active Pending
- 2020-05-01 US US16/864,891 patent/US20210198252A1/en not_active Abandoned
-
2021
- 2021-10-10 IL IL287113A patent/IL287113A/en unknown
- 2021-11-22 US US17/532,422 patent/US20230101819A1/en not_active Abandoned
-
2022
- 2022-07-25 JP JP2022118248A patent/JP2022163087A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009518423A (ja) * | 2005-12-08 | 2009-05-07 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | 統合失調症の副作用および陰性症状を治療するためのcb1アンタゴニストの使用 |
| JP2009542809A (ja) * | 2006-07-12 | 2009-12-03 | メルク エンド カムパニー インコーポレーテッド | グレリン受容体アンタゴニストとしての置換ピラゾール |
| WO2012168361A1 (en) * | 2011-06-10 | 2012-12-13 | Syngenta Participations Ag | Novel insecticides |
| JP2014517019A (ja) * | 2011-06-17 | 2014-07-17 | バジリア ファルマスーチカ アーゲー | 三環式抗生物質 |
Non-Patent Citations (2)
| Title |
|---|
| ALKER, A. ET AL., BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 20, JPN6019029019, 2010, pages 4521 - 4525, ISSN: 0004247325 * |
| STN REGISTRY FILE, JPN7019002365, 13 June 2008 (2008-06-13), ISSN: 0004247326 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021536428A (ja) * | 2018-08-14 | 2021-12-27 | エピザイム,インコーポレイティド | 置換インドール及びその使用方法 |
| JP7627209B2 (ja) | 2018-08-14 | 2025-02-05 | エピザイム,インコーポレイティド | 置換インドール及びその使用方法 |
| JP2025063306A (ja) * | 2018-08-14 | 2025-04-15 | エピザイム,インコーポレイティド | 置換インドール及びその使用方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2960275A1 (en) | 2016-03-17 |
| US20170355695A1 (en) | 2017-12-14 |
| WO2016040505A1 (en) | 2016-03-17 |
| MX2023006257A (es) | 2023-06-19 |
| EP3193600A4 (en) | 2018-05-23 |
| US20230101819A1 (en) | 2023-03-30 |
| EP3193600A1 (en) | 2017-07-26 |
| IL287113A (en) | 2021-12-01 |
| CN115028619A (zh) | 2022-09-09 |
| EA201790317A1 (ru) | 2018-07-31 |
| CN107072205B (zh) | 2022-07-15 |
| AU2015315174B2 (en) | 2019-12-12 |
| JP2020090520A (ja) | 2020-06-11 |
| AU2015315174A1 (en) | 2017-03-16 |
| US10266526B2 (en) | 2019-04-23 |
| KR20170045749A (ko) | 2017-04-27 |
| CN107072205A (zh) | 2017-08-18 |
| IL250891A0 (en) | 2017-04-30 |
| SG11201701598PA (en) | 2017-03-30 |
| JP2022163087A (ja) | 2022-10-25 |
| SG10201901192TA (en) | 2019-03-28 |
| BR112017004612A2 (pt) | 2018-01-30 |
| KR20230026515A (ko) | 2023-02-24 |
| US20190322660A1 (en) | 2019-10-24 |
| US20210198252A1 (en) | 2021-07-01 |
| KR102496364B1 (ko) | 2023-02-06 |
| MX2017002985A (es) | 2017-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102496364B1 (ko) | Smyd 억제제 | |
| US9187464B2 (en) | TRPV4 antagonists | |
| US10577363B2 (en) | Substituted piperidine compounds | |
| EP3193604B1 (en) | Substituted n-(pyrrolidin-3-yl)isoxazole-3-carboxamide compounds | |
| US10428029B2 (en) | Isoxazole carboxamide compounds | |
| CA2960277A1 (en) | Substituted pyrrolidine carboxamide compounds | |
| JP2017527576A (ja) | 置換シクロヘキシルアミン化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180910 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180910 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190620 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190730 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20191018 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200415 |